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Abstract
Background: In esophageal cancer, nutritional challenges are extremely com-
mon. Malignant obstruction resulting from esophageal cancer (EC) is often trea-
ted by the insertion of expandable stents, but little is known as to the role and
evolution of sarcopenia in this patient population. The aim of this article was to
determine the effects of body mass parameters on survival of advanced EC
patients who received a stent for palliation of malignant obstruction.
Methods: This was a retrospective observational study of 238 EC patients who
had a stent inserted for palliation of malignant obstruction between 2005 and
2013. Skeletal muscle mass was calculated from abdominal computed tomogra-
phy scans, and the patients were divided into sarcopenic and non-sarcopenic
groups. A follow-up computed tomography scan was available in 118 patients.
The primary outcome was survival, and complication rates and the need for an
alternative enteral feeding route were secondary outcomes.
Results: Sarcopenia occurred in 199 (85%) patients. Median survival was
146 (range: 76–226) days in the sarcopenia group and 152 (range: 71–249) days
in the non-sarcopenic group (P = 0.61). Complication rates between the groups
were not significantly different (P = 0.85). In Cox regression analysis, the skeletal
muscle index was inversely correlated with overall survival (hazard ratio 0.98,
95% confidence interval 0.97–0.99; P = 0.033).
Conclusions: Sarcopenia, defined by consensus thresholds, at the time of stent
insertion cannot effectively predict poor survival in this patient cohort, but a
lower skeletal muscle index correlates with poor prognosis as a continuous
variable.
Introduction
Esophageal cancer (EC) is a major cause of cancer mortal-
ity and morbidity worldwide, with approximately 455 800
new cases diagnosed and 400 200 deaths annually.1
EC patients commonly present with symptoms of dys-
phagia and weight loss.2 These symptoms are associated
with a higher mortality from EC.3 Sarcopenia represents a
new means to measure the degree of body composition
changes and cancer cachexia.4,5 The definition of sarcope-
nia is a skeletal muscle index (SMI) of ≤ 39 cm2/m2 for
women and ≤ 55 cm2/m2 for men by international
validated consensus.5,6 Measurement of SMI can involve
axial computed tomography (CT) imaging studies. In EC
patients who undergo esophagectomy, sarcopenia has been
linked to poor long-term outcome and postoperative respi-
ratory complications,7,8 and is also associated with poor
long-term outcomes in liver, pancreatic, breast, urothelial,
and colorectal cancers.9–13 Sarcopenia is related to the
dose-limiting toxicity of chemotherapeutic agents in hepa-
tocellular and renal cell carcinomas and breast cancer.14–18
Advanced EC often causes malignant obstruction, which
is widely treated with palliative insertion of a self-
expandable metallic stent (SEMS) and quickly and
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efficiently relieves dysphagia.19,20 Use of covered SEMS and
bare metal stents has been deemed safe by prospective ran-
domized trials.21,22
The purpose of this study was to assess the prognostic
significance of sarcopenia at the time of stent insertion in
patients receiving a SEMS for palliation of malignant
obstruction from advanced EC, and the effect of body mass
loss on survival during follow-up.
Methods
This was a retrospective cohort study. The Helsinki Uni-
versity Hospital (HUH) academic review board granted an
institutional study permit for the review of relevant
medical records.
Data collection and study parameters
Data was collected retrospectively from HUH medical
records. Patients who received a stent for palliation of
malignant obstruction caused by uncurable advanced EC
between 2005 and 2013 were candidates for inclusion.
The availability of electronic medical records regarding
stenting data dictated the selected time period. The time-
frame for an acceptable CT image was  two weeks
from stent insertion. A second CT image, if available,
served to assess body composition changes over time.
The acceptable time frame for this CT image was two to
six months after SEMS insertion. No patients were lost
to follow-up.
We collected the following data from our center’s medi-
cal records: demographic parameters, patients’ comorbidity
status, details of stent insertion, details of tumor type and
location, oncologic therapy administered, time of death,
and details related to stent complications.
The primary end point was overall survival (OS), defined
as the number of days from stent insertion to death. Sec-
ondary outcomes were the need for alternative enteral
feeding route, that is, percutaneous endoscopic gastro-
stomy (PEG) or jejunal feeding tube, and complications
resulting from the stent insertion.
Stent-insertion protocol
Indications for stenting were dysphagia and evidence of
obstructive tumor growth in gastroscopy. The stents were
placed under propofol sedation, without intubation, using
the standard technique over guidewires and with the help
of fluoroscopy. Tumor location, as well as the length and
severity of the stricture, determined the size and location
of the stent. Stent position was confirmed endoscopically
and radiologically.
Oncological treatments and follow-up
Patients who received a stent before or during definitive or
neoadjuvant chemotherapy or chemoradiation therapy
were followed-up in the medical oncology unit as standard
during their treatments and were evaluated for the need
for surgery by the esophageal surgery unit after the com-
pletion of therapy. These patients underwent follow-up
imaging to assess the tumor response to treatments.
Patients that were not fit for definitive treatments were fol-
lowed in a non-standardized manner depending on the
treatment regimen administered (chemotherapy, chemora-
diation, radiation or surveillance). These patients under-
went follow-up imaging to either monitor the progress of
the disease or to evaluate the effect of oncological
treatments.
Image analysis
We selected a single image on the level of L3, with both
transverse processes visible and imported it to OsirIX Ver-
sion 3.3 (32-bit Pixmeo, OsirIX, Sarl, Switzerland).
Abdominal muscles were delineated by the use of a semi-
automated selection of region of interest (ROI). The
Hounsfield Unit (HU) threshold range for skeletal muscle
was −29 to +150. When required, images were manually
corrected using the propulsion and brush tools in OsirIX.
The cross-sectional total muscle area (TMA) at the level of
L3 was assessed, and the skeletal muscle index (SMI) was
calculated by TMA/(height2); the resulting unit of mea-
surement was cm2/m2. Sarcopenia was defined as an SMI
of ≤ 39 cm2/m2 for women and ≤ 55 cm2/m2 for men, as
recommended by international validated consensus
statement.5
Statistical analysis
All statistical analysis was performed using R Project
(R Core Team, 2016, R Foundation for Statistical Comput-
ing, Vienna, Austria, URL: https://www.R-project.org/).
Variables are presented as mean and standard deviation
for normally distributed variables and as median and inter-
quartile range (IQR) for non-normally distributed vari-
ables. Normality of variables was calculated using the
Shapiro–Wilks test. Variables were compared using the
Mann–Whitney U test for non-normal continuous vari-
ables and the Student’s t-test for normally distributed con-
tinuous variables. Correlations were measured by Pearson
product moment correlation. The Kaplan–Meier method
was used for survival analysis. Cox multivariate regression
analysis was performed using the backwards elimination
method with a P value limit of 0.2. The limit for statistical
significance of P values was set at 0.05.
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Results
A total of 279 patients were identified and their records
were analyzed for inclusion; 41 patients had missing data
and/or inadequate CT scans and were thus excluded,
resulting in a study population of 238 patients.
Table 1 shows the characteristics and muscle parameters
of the study population (n = 238), and the subgroups. A
total of 199 (83.6%) patients had sarcopenia at the time of
stenting. There were no statistically significant differences
in age, gender, weight loss within three months of stenting,
Charlson Comorbidity Index (CCI), tumor histology, loca-
tion, tumor node metastasis (TNM) stage, or amount of
previous or post-stent oncological treatment between the
groups. Statistically significant differences were observed in
weight and height, body mass index (BMI), TMA, and
SMI; 36 (15.1%) patients had missing data in the weight
loss variable. Follow-up lasted until death for all
234 patients. The median duration between the diagnosis
of cancer and stenting was 19 days (range: 7–39). In
Table 1 Characteristics of the patient population
Characteristic
All Sarcopenia No sarcopenia
P(n = 238) (n = 199) (n = 39)
Mean SD Mean SD Mean SD
Age, years 67.52 10.895 68.12 10.481 64.31 12.561 0.35
Gender N % N % N % 0.408
Male 159 66.8% 142 71.4% 17 43.6%
Female 79 33.2% 57 28.6% 22 56.4%
Esophageal cancer histology 0.102
SCC 110 46.2% 94 47.2% 14 35.9%
AC 108 44.5% 88 44.2% 22 56.4%
Other 20 9.3% 18 8.6% 3 7.7%
Primary tumor location 0.315
Proximal third 22 9.2% 20 10.1% 2 5.1%
Middle third 114 47.9% 96 48.2% 18 46.2%
Distal third 102 42.9% 83 41.7% 19 48.7%
TNM stage
T2 2 0.8% 2 1.0% 0 0% 0.807
T3 130 54.6% 108 54.3% 22 56.4%
T4 106 44.5% 89 44.7% 17 43.6%
N0 25 10.5% 20 10.1% 5 12.8% 0.770
N1 139 58.4% 115 57.8% 24 12.1%
N2 51 21.4% 45 22.6% 6 15.4%
N3 23 9.7% 19 9.5% 4 10.3%
M1 94 39.5% 76 38.2% 18 46.2% 0.453
Recurrent tumor† 6 2.5% 6 3.0% 0 0% 0.589
Previous oncological treatment 0.205
Chemotherapy 7 2.9% 5 2.5% 2 5.1%
Radiation 8 3.4% 7 3.5% 1 2.6%
Chemoradiation 18 7.6% 18 9.0% 0 0%
Oncological treatments after stent 0.054
Chemotherapy 53 22.3% 42 21.1% 11 28.2%
Radiation 61 25.6% 48 24.1% 13 33.3%
Chemoradiation 41 17.2% 37 18.6% 4 10.3%
Muscle parameters median IQR median IQR median IQR
TMA 104.5 81.9–132.4 101.7 80.1–128.7 134.8 115.1–173.8 < 0.001
SMI 36.3 29.0–45.3 35.2 27.8–40.7 52.8 44.3–55.9 < 0.001
Weight, kg 63 55–74 62 54–72 75 61.6–88 < 0.001
Height, cm 173 164–179 173 165–179 168.5 158–175.8 0.003
BMI kg/m2 21.7 19.2–24.5 21 18.5–23.7 26.4 23.5–30.7 < 0.001
Weight loss, kg 10 7,5–17 10 7,5–17 10 7.3–17.3 0.806
CCI 7 5–9 7 5–9 7 6–11.0 0.384
†All six were recurrences after definitive chemotherapy or chemoradiation treatment. AC, adenocarcinoma; BMI, body mass index; CCI, Charlson
Comorbidity Index; IQR, interquartile range; SCC, squamous cell carcinoma; SD, standard deviation; SMI, skeletal muscle index; TMA, total muscle
area; TNM, tumor node metastasis.
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30 (12.6%) patients, the delay between diagnosis and stent
insertion was 180 days. Most patients (n = 196, 82.4%)
were not candidates for definitive treatment (surgery or
chemoradiation), the disease was thought to be incurable
in 114 patients (47.9%), 72 patients (30.3%) were evaluated
as unable to tolerate curative intent treatment because of
poor performance status, and 10 patients (4.2%) refused
curative treatment. The mean SMI for men was 39.4 cm2/
m2 and for women was 35.3 cm2/m2.
No significant differences between the groups as to stent
type, location, size, or complications were observed
(Table 2). The overall frequency of complications was
31.1% (n = 74). The most common complication was
migration of the stent, which occurred in 29 patients
(12.2%). No fatal complications were observed in this
cohort.
A total of 119 (49.6%) patients had an adequate second
CT scan. The indications for CT scanning were: monitor-
ing of oncological treatment response in 68 (57.6%), other
oncological follow-up in 32 (27.1%), and acute disease in
18 (25.3%) patients. The median interval to the second
scan was 91 days (range: 61–113); 108 patients (91.5%)
were sarcopenic, and 10 (8.5%) were non-sarcopenic in this
group. Table 3 shows the characteristics of these groups.
Age, TMA, and SMI significantly differed between the
groups. Of the 119 patients, 90 (75.6%) had sarcopenia in
both CT imaging studies, 19 (8%) had no sarcopenia in the
initial imaging but later developed sarcopenia, 6 (2.5%)
initially had sarcopenia but had no sarcopenia in the sec-
ond CT scan, and 4 (1.7%) had no sarcopenia in either of
the imaging studies. The mean SMI for this population was
36.5 cm2/m2 for men and 32.1 cm2/m2 for women; the dif-
ferences between mean pre-stent and post-stent insertion
were statistically significant for men (P = 0.016), but not
for women (P = 0.050).
The median OS was 146 days (range: 73–226) from stent
insertion. The median OS of the sarcopenic patients was
146 days (range: 76–226) and 152 (range: 71–249) in
patients without sarcopenia. Figure 1a shows Kaplan–
Meier survival analysis between the groups with no
significant difference (logrank P = 0.61). The presence of
sarcopenia was associated with a later need for PEG or a
jejunal feeding tube (P = 0.012).
The median OS in the group with sarcopenia in the sec-
ond imaging was 177 days (range: 119–236) and 352 (range:
243–512) in those without sarcopenia. Figure 1b shows
Kaplan–Meier analysis between these groups (logrank
P = 0.0024).
The median OS of patients who received a follow-up CT
scan was 189 days (range: 125–257), whereas the median
OS in patients who did not was 97 days (range: 38–189)
(P = 0.001).
Two groups were formed based on the percentage SMI
change (ΔSMI) in the follow-up period. The median ΔSMI
(−11.6%) served as a cutoff value. There were 59 patients
in each group. The median OS in group 1 (ΔSMI over
Table 2 Stent characteristics
Characteristics All (n = 238) Sarcopenia (n = 199) No sarcopenia (n = 39) P
Stent type 0.425
Ultraflex 218 91.6 181 91 37 94.9
Polyflex 7 2.9 6 3 1 2.6
Microtec 3 1.3 4 2 0 0
Antireflux 4 1.7 3 1.5 0 0
Other 6 2.5 5 2.5 1 2.6
Beginning stent location 134 56.3 114 57.3 20 51.3 0.547
Below 30 cm
Above 30 cm 104 43.7 85 42.7 19 48.7
Stent Size 0.435
15 cm 37 15.5 33 16.6 4 10.3
12 cm 95 39.9 80 40.2 15 38.5
10 cm 84 35.3 68 34.2 16 41
Other 10 4.2 9 4.5 1 2.6
N/A† 12 5 9 4.5 3 7.7
Complications 0.85
Any 74 31.1 61 30.7 13 33.3
Migration 29 12.2 24 12.1 5 12.8
Bleeding 6 2.5 23 11.6 2 5.1
Fistula 25 10.5 7 3.5 1 2.6
Perforation 8 3.4 6 3 2 5.1
Infection 10 4.2 8 4 2 5.1
†Not specified in operative report.
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median) was 190 days (range: 140–325) and the median
OS in group 2 (ΔSMI under median) was 178 (range:
117–235). Figure 2 shows the Kaplan–Meier analysis of OS
between these groups (P = logrank P = 0.018). ΔSMI was
correlated with OS as a continuous variable
(P = 0.013, r = 0.21).
Backwards-eliminating Cox proportional hazards analy-
sis was performed to elucidate the relationship between
SMI and OS. Predictors included in the initial model were
age, gender, BMI, weight loss, CCI, EC histology, clinical
TNM status, previous treatments, treatments after stenting,
non-curative intent of treatments, location of EC, and SMI.
There were 238 events with 6 covariates in the final model,
resulting in an event per predictor variable ratio of 39, well
over the suggested limit of 10.23 Table 4 shows the final
Cox model. SMI, age, treatment after stent, and CCI were
significantly associated with OS in the final model, whereas
clinical N-stage and non-curative intent of treatment did
not reach significance but could not be excluded from the
model because P < 0.2. A higher CCI score produced a
higher risk of death (hazard ratio [HR] 1.13, 95% confi-
dence interval [CI] 1.06–1.20; P < 0.001) whereas both
patient age (HR 0.98, 95% CI 0.96–0.99; P < 0.001) and
SMI (HR 0.98, 95% CI 0.97–0.99; P = 0.033) were inversely







(n = 10) P
Age, years 65.8 9.9 66.4 9.7 60.1 10.4 0.043
Gender 0.371
Male 80 67% 72 66% 8 80%
Female 39 33% 37 34% 2 20%
Weight, kg 65 55–77 64 55–77.5 69 60–74.8 0.612
Height, cm 173 165–179 173 164.5–179 173 164.5–178.3 0.799
BMI, kg/m2 22.3 20.0–24.9 22 19.6–24.7 23.5 21.7–25.6 0.427
Weight loss, kg 10 7–17 10 7.5–17 10 5–15 0.58
CCI 6.8 2.1 6.8 1.6 7.1 1.6 0.725
Muscle parameters
TMA†, m2 101.6 85.1–119.1 97.1 83.2–116.4 131.9 115.9–161.7 0.001
SMI‡, m2/cm2 35.4 29.6–40.0 33.5 28.8–38.3 45.3 40.0–53.4 0.000
SMI Change −4.1 −8.9-(−0.3) −4.3 −9.1-(−0.8) −1.3 −5.4-1.3 0.073
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Time (months)
199 140 79 40 23 10 8 4 2 1 0
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a Number at risk
108 96 53 21 12 4 2 0
10 10 8 7 4 3 2 1
0 3 6 9 12 15 18 21
Time (months)
Sarcopenia Yes No
a bFigure 1 Kaplan–Meier survival
curve for overall survival between
patients with and without
sarcopenia at (a) initial and (b)
follow-up imaging.
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correlated with OS. Treatment received after stenting low-
ered the risk of death (HR 0.56, 955 CI 0.41–0.76;
P < 0.001).
Discussion
Sarcopenia, measured by muscle area from an abdominal
CT scan at the level of the L3 lumbar vertebra, was not sig-
nificantly associated with poorer survival (P = 0.61). An
association existed between sarcopenia in a later imaging
study, taken on average 91 days after the initial CT, and
poorer survival (P = 0.0024). Multivariate analysis showed
an inverse correlation between SMI and OS (HR 0.98, 95%
CI 0.97–0.99; P = 0.033), meaning that a more pronounced
loss of muscle mass had a negative effect on survival. These
results indicate that although the traditionally defined sar-
copenia cutoffs do not produce a statistically significant
correlation with OS, SMI has predictive value as a variable
and a lower SMI is correlated with poor survival.
There were no statistical differences in the clinical T, N,
or M-stages between patients with and without sarcopenia
in our study, indicating that other factors contributed to
the amount of sarcopenia aside from the tumor stage. Sar-
copenic patients received fewer oncological treatments after
stent insertion (P = 0.054), but this result was not statisti-
cally significant; this may be explained by the fact that phy-
sicians were more conservative when offering treatment
options to sarcopenic patients because of their overall poor
performance status.
There was a statistically significantly correlation between
sarcopenia and a later need for an alternative feeding route
(P = 0.012). This implies that sarcopenia might impact
clinical decision-making when the success of stenting and
the need for further interventions are considered. Recur-
rent tumor growth through the stent may also lead the cli-
nician to seek an alternative permanent solution to the
enteral feeding route. Some patients may also prefer the
PEG insertion to stenting. In cases of more aggressive
tumor metabolism and inflammation, interventions to
maintain an enteral feeding route may become futile, and
these patients may be unable to overcome their catabolic
state by enteral feeding alone.
Researchers are increasingly interested in sarcopenia in
cancer. The incidence of malnutrition, dysphagia, and
weight loss among EC patients is among the highest of all
cancers.2,3 These symptoms are correlated with sarcopenia
incidence.24 Sarcopenia can also cause dysphagia in the
elderly, with OS in EC patients who underwent esophageal
resection negatively affected by sarcopenia.7 To our knowl-
edge, no data exists on the effect of sarcopenia or SMI in
EC patients who receive a stent for palliation of dysphagia.
However, poor nutrition evaluated by weight, BMI, and
albumin concentration is linked to poorer survival in
advanced or recurrent EC patients who receive stents.19
Sarcopenia may reflect more aggressive tumor biology, sys-
temic inflammation, and metabolic activity.25 It cannot be
assessed by clinical measurements, because many sarcope-
nic patients have a normal BMI.25–27 Sarcopenia can even
coexist with obesity,10,12,24 making abdominal CT scans
necessary and a widely used method to precisely measure
the degree of sarcopenia.6–9,11–15,17,28,29 The magnitude of
the effect of SMI on OS is small per measurement unit
(HR 0.98), similar to patient age, but as this is a cumulative



















SMI loss in follow−up Group 2 Group 1
59 52 29 10 4 0 0 0
59 54 32 18 12 7 4 1














Figure 2 Kaplan–Meier survival curve of overall survival between
patients with greater than median skeletal muscle index (ΔSMI) loss
(−11.6%, group 2) versus patients with less than median ΔSMI loss
(group 1).
Table 4 Multivariate Cox regression analysis of overall survival
Variable HR 95% CI P
Age 0.98 0.96–0.99 < 0.001
CCI† 1.13 1.06-1.20 < 0.001
Skeletal muscle index 0.98 0.97–0.99 0.033
cN 0.87 0.74–1.04 0.122
Non-curative intent 0.75 0.51–1.08 0.123
Treatment after stent† 0.56 0.41–0.76 < 0.001
†Chemotherapy, radiation, or chemoradiation. CCI, Charlson Comor-
bidity Index; CI, confidence interval; HR, hazard ratio.
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significant. Only 6 (5,1%) patients in the follow-up popula-
tion were cured of their sarcopenia post-stenting, and the
mean SMI dropped both in men and women during
follow-up. The percentage of muscle mass lost (ΔSMI)
during follow-up produced clearly stratified survival curves
when the median ΔSMI (−11.6%) was used as a threshold.
In our study, the treatment received after stenting seemed
to correlate with better OS, but this should be interpreted
carefully, as patients offered treatments after stenting tend
to have better performance status than those who are not
offered any additional treatment.
Our study has a number of limitations, including its ret-
rospective design. Groups were neither matched nor ran-
domized. There is a risk of a type II error because of the
low expected OS in this patient population and our rela-
tively small control population. Furthermore, our institute
has no specific follow-up program after stent insertion for
patients at this stage of the disease; the frequency of
follow-up CT imaging was low and its timing varied, in
part to the lack of systemic follow-up and in part to the
overall poor survival of this patient group.
Our results may indicate that in the setting of end-stage
EC, lower muscle mass predicts poor prognosis. Sarcopenia
defined by traditional skeletal muscle mass thresholds does
not correlate with prognosis in this patient group.
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